The Official Website of the Long-Term Investor
Results 1 - 10 of 105 : 1 2 3 4 5 6 7 8 9 Next
This Dividend Stock Just Pushed up Its Payout
Can this utility electrify your earnings?
Ameren Earnings: 1 Dividend That's Here to Stay
The utility opts for regulation over generation.
Why Repros Is Poised to Keep Plunging
Market-lagging returns could be written in this 1-Star.
Does This Pharma Have Spinout Envy?
While other big pharmas are spinning out businesses, Merck stays on course.
Will These Risks Crush Questcor in 2013?
What are the biggest overhangs facing this biotech company?
The Best Way You Can Play the Fiscal Cliff Deal
Congress provided a two-for-one deal for smart investors.
Can Antares' Products Power Your Portfolio in 2013?
Does Antares have the products to power your portfolio in 2013?
The Future Arrives for Abbott Labs
On the first day of the new Abbott, what should you watch for this revamped company's future?
A Big Decision Coming for Big Pharma: Part 3
As the Supreme Court moves forward considering pay-for-play, the specific impacts are dependent on the specific company’s role in the industry.
Profiting From SCOTUS and Big Pharma: Part 2
The Supreme Court's investigation of brand-name and generic drug maker’s agreements involves two significant areas of law.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK